Press releases
- 4basebio Plc - 4basebio client's Phase I clinical trials for opDNA™ based mRNA vaccine
- 4basebio Plc - 4basebio awarded tender to deliver research and GMP-grade synthetic DNA in CPI's tender process for supplying its RNA Centre of Excellence
- 4basebio Plc - Holding(s) in Company
- 4basebio Plc - Exercise of Options
- 4basebio Plc - Directors' Dealings
- 4basebio Plc - Long-Term Incentive Plan and Exercise of Options
More ▼
Key statistics
As of last trade 4Basebio PLC (88Q:FRA) traded at 10.80, -5.26% below its 52-week high of 11.40, set on Mar 15, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 10.70 |
---|---|
High | 11.00 |
Low | 10.70 |
Bid | 10.80 |
Offer | 11.00 |
Previous close | 10.80 |
Average volume | 482.44 |
---|---|
Shares outstanding | 12.81m |
Free float | 1.92m |
P/E (TTM) | -- |
Market cap | 121.65m GBP |
EPS (TTM) | -0.5094 GBP |
Data delayed at least 15 minutes, as of Mar 28 2024 08:59 BST.
More ▼